564 related articles for article (PubMed ID: 30744563)
1. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
Floros L; Pagliuca A; Taie AA; Weidlich D; Rita Capparella M; Georgallis M; Sung AH
J Med Econ; 2020 Jan; 23(1):86-97. PubMed ID: 31262225
[No Abstract] [Full Text] [Related]
3. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.
Azanza JR; Grau S; Vázquez L; Rebollo P; Peral C; López-Ibáñez de Aldecoa A; López-Gómez V
Mycoses; 2021 Jan; 64(1):66-77. PubMed ID: 32989796
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.
Harrington R; Lee E; Yang H; Wei J; Messali A; Azie N; Wu EQ; Spalding J
Adv Ther; 2017 Jan; 34(1):207-220. PubMed ID: 27913989
[TBL] [Abstract][Full Text] [Related]
5. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.
Bagshaw E; Enoch DA; Blackney M; Posthumus J; Kuessner D
Future Microbiol; 2018 Sep; 13(11):1283-1293. PubMed ID: 29911889
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China.
Han G; Xu Q; Lv Q; Li X; Shi X
Front Public Health; 2023; 11():1292162. PubMed ID: 38179563
[TBL] [Abstract][Full Text] [Related]
7. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.
Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF
J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060
[TBL] [Abstract][Full Text] [Related]
8. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.
Bagshaw E; Kuessner D; Posthumus J; Escrig C; Blackney M; Heimann SM; Cornely OA
Future Microbiol; 2017 May; 12():515-525. PubMed ID: 28191796
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands.
Jansen JP; Meis JF; Blijlevens NM; van't Wout JW
Curr Med Res Opin; 2005 Oct; 21(10):1535-46. PubMed ID: 16238893
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
12. New pharmacological opportunities for the treatment of invasive mould diseases.
Ledoux MP; Toussaint E; Denis J; Herbrecht R
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i48-i58. PubMed ID: 28355467
[TBL] [Abstract][Full Text] [Related]
13. Economic and budgetary impact evaluation of isavuconazole (Cresemba®) versus voriconazole (Vfend®) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system.
Araujo GLV; Murta Amaral L; Ponzio V; Rocha JL
PLoS One; 2024; 19(3):e0299056. PubMed ID: 38427635
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
Shirley M; Scott LJ
Drugs; 2016 Nov; 76(17):1647-1657. PubMed ID: 27766566
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada.
Beauchemin C; Guinan K; Claveau D; Dufresne SF; Rotstein C
Expert Rev Pharmacoecon Outcomes Res; 2022 Jul; 22(5):805-814. PubMed ID: 34524935
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
18. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
Garbino J; Schnetzler G; Roberts C
Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508
[TBL] [Abstract][Full Text] [Related]
19. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
[TBL] [Abstract][Full Text] [Related]
20. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]